Gilead Sciences, Inc.
GILDHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. At a $166.90B market cap, Gilead Sciences, Inc. ranks as a large-cap company within healthcare. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Market Cap
$166.90B
Beta
0.33
P/E (TTM)
18.29
P/E (Fwd)
14.02
EPS (TTM)
$7.35
EPS (Fwd)
$9.59
ROE
43.4%
ROA
13.3%
Cash
$9.82B
Total Debt
$22.17B
Free CF
$7.93B
52W Change
23.4%
Annual Financials
Cash vs Debt
The company holds $9.82B in cash, though total debt stands at $22.17B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $7.93B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 43.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 13.3% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $27.28B (2022) to $29.44B (2025).
GILD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. No single metric tells the full story. Reviewing GILD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.